Health Care & Life Sciences » Biotechnology | Galectin Therapeutics Inc.

Galectin Therapeutics Inc. | Ownership

Companies that own Galectin Therapeutics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
The Vanguard Group, Inc.
1,200,351
2.93%
40,709
0%
06/30/2018
D.A. Davidson & Co. (Investment Management)
656,527
1.61%
-74,773
0.08%
06/30/2018
BlackRock Fund Advisors
583,022
1.43%
392,345
0%
06/30/2018
SagePoint Financial, Inc. (Investment Management)
580,450
1.42%
29,580
0.24%
06/30/2018
Susquehanna Financial Group LLLP
357,793
0.88%
304,328
0.01%
06/30/2018
Benchmark Capital Advisors, Inc.
221,700
0.54%
0
1.07%
06/30/2018
EAM Investors LLC
218,429
0.53%
-100,758
0.19%
06/30/2018
Geode Capital Management LLC
202,563
0.5%
7,152
0%
06/30/2018
EAM Global Investors LLC
164,511
0.4%
-62,552
0.48%
06/30/2018
Group One Trading LP
108,491
0.27%
103,339
0.05%
06/30/2018

About Galectin Therapeutics

View Profile
Address
4960 Peachtree Industrial Boulevard
Norcross Georgia 30071
United States
Employees -
Website http://www.galectintherapeutics.com
Updated 07/08/2019
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs targets the development of carbohdrate molecules which offers offer alternative options to larger market segments. The company was founded by James C.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.